Risk evaluation and mitigation strategies: Impact on patients, health care providers, and health systems

Shane, Rita
December 2009
American Journal of Health-System Pharmacy;12/15/2009, Vol. 66 Issue 24, pS6
Academic Journal
The article reports on the move of the U.S. Food and Drug administration (FDA) to conduct workshops on risk minimization action plans (RiskMAPs) for drug safety. It notes that the FDA was urged by a 2006 Institute of Medicine (IOM) report to the U.S. Congress, which has criticized its move to withdraw drugs due to safety concerns. Meanwhile, the said workshops aim to acquire information on medications risk minimization that evolves under the risk evaluation and mitigation strategies (REMS).


Related Articles

  • The US FDA requires a "new vision of drug safety.".  // Reactions Weekly;11/4/2006, Issue 1126, p3 

    The article reports on the recommendation of the Institute of Medicine Committee on the Assessment of the U.S. Drug Safety System for U.S. Food and Drug Administration to acquire a culture of safety in which the risks and benefits of medications are examined during their entire market life. The...

  • Institute of Medicine Report Slams FDA.  // Quality Progress;Nov2006, Vol. 39 Issue 11, p16 

    The article reports on an independent federal report from the United States Institute of Medicine. The report echoes the harshest critics of the U.S. Food and Drug Administration's drug safety regimen. According to the report, the drug safety system of the country is feeble in its drug approval...

  • Institute of Medicine, Congress Seek Solutions to FDA's Safety Woes Through Reform, Funding. Finkelstein, Joel B. // JNCI: Journal of the National Cancer Institute;1/17/2007, Vol. 99 Issue 2, p104 

    The article reports on the findings of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System, regarding the lack of certainty over safety of new drugs as approved by the Food and Drug Administration (FDA). According to sources, it is not a question of ability,...

  • Risk management Shapes FDA Policies and Practices. Wechsler, Jill // Pharmaceutical Technology North America;Aug2002, Vol. 26 Issue 8, p12 

    Reports on initiatives of U.S. Federal Drug and Administration (FDA) to prompt manufacturers to assess and address drug safety issues. Importance of identifying risks associated with the use of medical products to reduce adverse events; Need for additional funding to enhance adverse-event data...

  • Accelerating Drug Development. Wechsler, Jill // Pharmaceutical Technology;Mar2007, Vol. 31 Issue 3, p32 

    The article focuses on a report plans by the U.S. Food and Drug Administration that addresses many of the drug-safety issues in response to a set of recommendations from the Institute of Medicine. The report "The Future of Drug Safety: Promoting and Protecting the Health of the Public" outlines...

  • FDA's Safe Use Initiative to address preventable harm due to medication misuse, errors, and other related problems.  // Formulary;Jan2010, Vol. 45 Issue 1, p29 

    The article discusses the U.S. Food and Drug Administration's Safe Use Initiative-Collaboration to Reduce Preventable Harm from Medications. The initiative was created to help address preventable problems such as medication misuse, errors and adverse side effects. According to the FDA, the...

  • Hospital Systems for the Detection and Prevention of Adverse Drug Events. Cheng, C. M. // Clinical Pharmacology & Therapeutics;Jun2011, Vol. 89 Issue 6, p779 

    In its 2006 report 'Preventing Medication Errors,' the Institute of Medicine (IOM) estimated that more than 1.5 million preventable adverse drug events (ADEs) occur annually in the United States. Many organizations, including the IOM, the Institute for Safe Medication Practices, the US Food and...

  • Specialty pharmacy's role in REMS, FDA's new drug safety program. Russek, Steven B. // Formulary;Oct2009, Vol. 44 Issue 10, p300 

    Prescription drug safety is a topic that generates a great deal of attention in the headlines, among patient communities, and in the US civil court system. A problem arises when a drug offers significant therapeutic benefits but also carries challenging health or safety risks. FDA recently...

  • Kaiser Questions Safety Policies. Wechsler, Jill // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p18 

    The article reports on the petition of Kaiser Permanente to the Food and Drug Administration (FDA) on the growing number of approved Risk Evaluation and Mitigation Strategies (REMS) with Elements to Assure Safe Use (ETASU) of drugs in the U.S. It mentions that Kaiser is concerned on the diverse...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics